AIM: £4.52 (-0.02) | Nasdaq: $29.49 (-0.51)
News Archive

Our latest announcements or presentations are available by selecting the desired News Type.

Announcements can be further filtered by topic using the News Topic check boxes.

 

The full text of all announcements are available for download in the form of PDF files.  For convenience, the text of some announcements have been partially or fully rendered as web pages.  Should any inconsistencies exist, the PDF version shall prevail.

News Type
Presentations
RNS Announcements
News Topics
Commercial Platform
Group
Innovation Platform
Regulatory Notice
1
23
found Documents: 107
Corporate presentations, Presentations | 1 Oct 2020

Corporate Presentation
Download Chinese Presentation (PDF)Download Presentation (with Appendix) (PDF)
Presentations, Scientific Publications | 21 Sep 2020

The Lancet Oncology: Surufatinib SANET-p phase 3 study
Surufatinib in advanced pancreatic neuroendocrine tumours (SANET-p): a randomised, double-blind, placebo-controlled, phase 3 study Jianming Xu*, Lin Shen*, Chunmei Bai*, Wei Wang*, Jie Li, Xianjun Yu, Zhiping Li, Enxiao Li, Xianglin Yuan, Yihe
Read More
Presentations, Scientific Publications | 21 Sep 2020

The Lancet Oncology: Surufatinib SANET-ep phase 3 study
Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 study Jianming Xu*, Lin Shen*, Zhiwei Zhou, Jie Li, Chunmei Bai, Yihebali Chi, Zhiping Li, Nong Xu, Enxiao Li, T
Read More
Presentations, Scientific Publications | 20 Sep 2020

ESMO2020: Surufatinib for patients with advanced pancreatic NET (SANET-p)
Title: Surufatinib (S) for patients (Pts) with advanced pancreatic neuroendocrine tumors (SANET-p): a randomized, double-blind, placebo (P)-controlled Phase III trial (NCT02589821) Lead Author: Jianming Xu, Head of the Department of Gast
Read More
Download Presentation (PDF)
Presentations, Scientific Publications | 18 Sep 2020

ESMO2020: Phase1/1b Trial of Fruquintinib in Patients with Advanced Solid Tumors
Title: Phase (Ph) 1/1b Trial of Fruquintinib (Fru) in Patients (Pts) with Advanced Solid Tumors: Preliminary Results of the Dose Expansion (Exp) Cohort in Refractory Metastatic Colorectal Cancer (mCRC) Lead Author: N. Arvind Dasari, Asso
Read More
View Poster (PDF)
Presentations, Scientific Publications | 18 Sep 2020

ESMO2020: SANET-ep study subgroup analysis by Ki-67 and primary tumor origins
Title: Subgroup analysis by Ki-67 and primary tumor origins of the randomized, placebo-controlled phase 3 study of surufatinib in advanced well-differentiated extrapancreatic neuroendocrine tumors (SANET-ep) Lead Author: Zhiwei Zhou, Dir
Read More
View Poster (PDF)
Corporate presentations, Event, Presentations | 1 Jun 2020

ASCO Investor Update
Press release released:  May 29, 2020 (Fri) >> See press release here Presentation webcast & call:  June 1, 2020 (Mon) 1pm GMT/ 8am EDT/ 8pm HKT >> Click here for the webcast replay  
Read More
Download Presentation (PDF)
Presentations, Scientific Publications | 27 Apr 2020

AACR2020: Comparison of Pharmacokinetic Profiles and Safety of Surufatinib in Patients from China and the United States
Title: Comparison of Pharmacokinetic Profiles and Safety of Surufatinib in Patients from China and the United States Presenter: Arvind Dasari Authors: A Dasari1, S Paulson2, E Hamilton3, J Wang4, M Sung5, G Falchook6, C Tucci7, K
Read More
Download Presentation (PDF)
Presentations, Scientific Publications | 27 Apr 2020

AACR2020: A Phase I Trial of Surufatinib plus Toripalimab in Patients with Advanced Solid Tumor
Title: A Phase I Trial of Surufatinib Plus Toripalimab in Patients with Advanced Solid Tumors Presenter: Yanshuo Cao Authors: M Lu1, Y Cao1, J Gong1, Y Sun2, J Li1, L Shen1. 1 Department of Gastrointestinal Oncology, Key Labor
Read More
Download Presentation (PDF)
Presentations, Scientific Publications | 13 Mar 2020

ENETS 2020 : Safety Profile and AESI for Surufatinib in Chinese Patients with Advanced Extra-Pancreatic Neuroendocrine Tumors: Analysis of the Phase 3 SANET-ep Trial
The previously reported SANET-ep trial (clinicaltrials.gov identifier NCT02588170) demonstrated that surufatinib significantly improves progression-free survival (“PFS”) in patients with advanced extrapancreatic (non-pancreatic) neuroendocrine tu
Read More
View Poster
Corporate presentations, Event, Presentations | 3 Mar 2020

2019 Full Year Results
Announcement released: 12 noon GMT (7am EST / 8pm HKT )  >> See announcement here Presentation webcast & call: 1pm GMT (8am EST / 9pm HKT) >> Click here for the webcast replay To participate by phon
Read More
Download Presentation (PDF)
Presentations, Scientific Publications | 6 Feb 2020

The Lancet Oncology: Osimertinib plus Savolitinib in EGFRm+, MET+ NSCLC
Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study Lecia V Sequist;
Read More
Corporate presentations, Presentations | 20 Jan 2020

Corporate presentation
Download Presentation (PDF)
Corporate presentations, Event, Presentations | 15 Jan 2020

38th Annual J.P. Morgan Healthcare Conference
Location: Westin St. Francis Hotel, San Francisco, CA Presentation Date: Wednesday Jan 15, 2020 Presentation Time: 01:00pm PST (04:00pm EST/09:00pm BST) Audio Recording: Please download the accompanying presentation. [audi
Read More
Download Presentation (PDF)
Corporate presentations, Event, Presentations | 13 Nov 2019

Deutsche Bank ADR Virtual Investor Conference (dbVIC)
Live virtual investor conference. Time: 01:30 pm GMT (09:30 pm HKT/08:30 am EST) >> Click here for the webcast  
Read More
Download Presentation (PDF)
Corporate presentations, Event, Presentations | 30 Sep 2019

Post-ESMO Surufatinib Update
Press release released:  September 29, 2019 (Sun)  >> See press release here Presentation webcast & call:  September 30, 2019 (Mon) 2pm CEST (1pm BST/8am EDT/8pm HKT) [audio mp3="https://www.chi-med.com/wp-content
Read More
Download Presentation (PDF)
Presentations, Scientific Publications | 29 Sep 2019

ESMO 2019: Efficacy and Safety of Surufatinib in Patients with Well-Differentiated Advanced Extrapancreatic NETs
Title:   Efficacy and Safety of Surufatinib in Patients with Well-Differentiated Advanced Extrapancreatic Neuroendocrine Tumors: Results from the Randomized Phase III Study (SANET-ep) Presenting Author: Jianming Xu, Head of th
Read More
Download Presentation (PDF)
Presentations, Scientific Publications | 21 Sep 2019

CSCO 2019: Association Between Hand-Foot Skin Reaction (HFSR) and Survival Benefit of Fruquintinib in FRESCO Trial
Presentation Title : Association Between Hand-Foot Skin Reaction and Survival Benefit of Fruquintinib in FRESCO Trial Presenting Author: Yuxian Bai, Harbin Medical University Cancer Hospital Other Authors: Jin Li, Shukui Qin, Yanho
Read More
Download Presentation (PDF)
Presentations, Scientific Publications | 19 Sep 2019

CSCO 2019 : Subgroup Analysis of Patients With Metastatic Colorectal Cancer Treated With Fruquintinib in the FRESCO Trial Who Had Liver Metastasis
Presentation Title : Subgroup Analysis of Patients With Metastatic Colorectal Cancer Treated With Fruquintinib in the FRESCO Trial Who Had Liver Metastasis Presenting Author: Shukui Qin, Nanjing Chinese Medicine University Affiliated Bay
Read More
Download Presentation (PDF)
Presentations, Scientific Publications | 9 Sep 2019

WCLC 2019: Phase III Fruquintinib v.s. Placebo in Advanced Non-Small Cell Lung Cancer (FALUCA)
MA14.05 - A Randomized Phase III Trial of Fruquintinib Versus Placebo in Patients with Advanced Non-Small Cell Lung Cancer (FALUCA)   Venue: IASLC 2019 World Conference on Lung Cancer in Barcelona, Spain Session:MA14 - The Adequate MTarget
Read More
Download Presentation (PDF)
Corporate presentations, Event, Presentations | 9 Sep 2019

CLSA Investors' Forum 2019
Grand Hyatt, Hong Kong
Download Presentation (PDF)
Corporate presentations, Event, Presentations | 30 Jul 2019

2019 Half-Year Financial Results
Announcement released: 7am BST (2pm HKT/2am EDT)  >> See announcement here Presentation webcast & call: 9am BST (4pm HKT/4am EDT) >> Click here for the webcast US conference call: 9am EDT (2pm BST/9pm HKT)
Read More
Download Presentation (PDF)
Presentations, Scientific Publications | 1 Jun 2019

Clin Cancer Res: Surufatinib in advanced, well-differentiated neuroendocrine tumors
Surufatinib in advanced well-differentiated neuroendocrine tumors: a multicenter, 3 single-arm, open-label, phase Ib/II trial Jianming Xu, Jie Li, Chunmei Bai, Nong Xu, Zhiwei Zhou, Zhiping Li, Caicun Zhou, Ru Jia, Ming Lu, Yuejuan Cheng, Chenyu Mao
Read More
Corporate presentations, Event, Presentations | 31 May 2019

Morgan Stanley Annual China Summit 2019
Rosewood Beijing
Download English Presentation (PDF)Download Chinese Presentation (PDF)
Corporate presentations, Event, Presentations | 8 May 2019

J.P. Morgan Global China Summit 2019
China World Summit Wing Hotel, Beijing
Download English Presentation (PDF)Download Chinese Presentation (PDF)
Corporate presentations, Event, Presentations | 11 Mar 2019

2018 Full Year Results
Announcement released: 7am BST (3pm HKT / 3am EDT) >> See announcement here Presentation webcast & call: 9am BST (5pm HKT / 5am EDT) >> Click here for the webcast US conference call: 9am EDT (1pm BST/9pm HKT
Read More
Download Presentation (PDF)
Corporate presentations, Event, Presentations | 7 Jan 2019

37th Annual J.P. Morgan Healthcare Conference
Location: Westin St. Francis Hotel, San Francisco, CA Presentation Date: Wednesday Jan 9, 2019 Presentation Time: 9:30am PST (12:30pm EST/5:30pm BST) Audio Recording: Please download the accompanying presentation. [audio m
Read More
Download Presentation (PDF)
Corporate presentations, Event, Presentations | 27 Jul 2018

2018 Half-Year Financial Results
  Announcement released: 7am BST (2pm HKT/2am EDT)  >> See announcement here Presentation webcast & call: 9am BST (4pm HKT/4am EDT) >> Click here for the webcast US conference call: 9am EDT (2pm BST/9
Read More
Download Presentation (PDF)
Presentations, Scientific Publications | 26 Jun 2018

JAMA: Fruquintinib vs Placebo in Previously Treated Metastatic Colorectal Cancer
Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer The FRESCO Randomized Clinical Trial Jin Li; Shukui Qin; Rui-Hua Xu; Lin Shen; Jianming Xu; Yuxian Bai; Lei Yang; Yanhong Deng;
Read More
Presentations, Scientific Publications | 4 Jun 2018

ASCO 2018: Colorectal cancer Q-TWiST with fruquintinib treatment in FRESCO
Quality-adjusted time without symptoms or toxicity (Q-TWiST) of patients with metastatic colorectal cancer treated with fruquintinib in FRESCO Presenter: Yu-Xian Bai Other Authors: Hongyan Li, Ning Wang, Xiaojun Guo, Wei Wang, Songhua F
Read More
View Poster
Presentations, Scientific Publications | 4 Jun 2018

ASCO 2018: Subgroup analysis by prior anti-VEGF or anti-EGFR target therapy in FRESCO
Presenter:     Ruihua Xu Other Authors: Jin Li, Yu-Xian Bai, Yanhong Deng, Lei Yang, Haijun Zhong, Zhendong Chen, Hongming Pan, Weijian Guo, Yongqian Shu, Ying Yuan, Jianming Xu, Lin Shen, Ning Wang, Xin Wang, Haidong Chi, Jack Peng, Y
Read More
Presentations, Scientific Publications | 17 Apr 2018

AACR 2018: MET gene copy number gains evaluated by NGS is more predictive than other methods to enrich for papillary RCC patients sensitive to savolitinib
4541 / 26 - MET gene copy number gains evaluated by NGS is more predictive than other methods to enrich for papillary RCC patients sensitive to savolitinib, a selective MET inhibitor Presenter/Authors M. M. Frigault1, S. Signoretti2, A. Markovets
Read More
View Poster
Presentations, Scientific Publications | 23 Mar 2018

ASCPT 2018: Fruquintinib Pharmacokinetics in Humans
Pharmacokinetics of Fruquintinib in Humans Venue: American Society for Clinical Pharmacology & Therapeutics Annual Meeting in Orlando, Florida, USA Abstract #: PII-116 Authors: Ke Li, Chen Yu, Yanmei Liu, Xiangkun Li, Sumei Xia, Jian Wa
Read More
Download Poster Presentation (PDF)
Corporate presentations, Event, Presentations | 12 Mar 2018

2017 Full Year Financial Results
Announcement released: 7am BST (3pm HKT/3am EDT) » See announcement here Presentation webcast & call: 9am BST (5pm HKT/5am EDT) » Click here for a video of the webcast US conference call: 9am EDT (1pm BST/9pm HKT)
Read More
View Presentation (PDF)
Presentations, Scientific Publications | 12 Mar 2018

Journal of Clinical Oncology: Phase II Trial of Fruquintinib in Patients with Advanced Nonsquamous NSCLC
 Shun Lu, Jianhua Chang, Xiaoqing Liu, Jianhua Shi, You Lu, Wei Li, Jin-ji Yang, Jianying Zhou, Jie Wang, Tongtong An, Lei Yang, Zhe Liu, Xiangdong Zhou, Mo Chen, Ye Hua and Weiguo Su Abstract Purpose Patients with advanced non‒small-cell lung
Read More
Presentations, Scientific Publications | 24 Feb 2018

ACOS 2018: Adverse Events of Special Interest Profiles and Time Courses of Fruquintinib in the FRESCO Trial
Venue: The 13th International Conference of the Asian Clinical Oncology Society in Chiang Mai, Thailand Abstract #: ABS093 Authors: Jin Li, Shukui Qin, Yuxian Bai, Yanhong Deng, Lei Yang, Zhendong Chen, Haijun Zhong, Rui-hua Xu, Hongming Pan,
Read More
Download Slides (PDF)
Presentations, Scientific Publications | 20 Feb 2018

ICTO2018: Phase Ib of Savolitinib and Durvalumab in Renal Cell Carcinoma (CALYPSO)
A Phase Ib Study of Durvalumab (MEDI4736) in Combination with Savolitinib in Patients with Metastatic Renal Cell Carcinoma S Vari1, B Szabados1, A GomezdeLiano1, K Mousa2, L Rammazzo2, A Prendergast2, T Powles1 1 Barts Health NHS Trust, Barts Can
Read More
Presentations, Scientific Publications | 17 Oct 2017

WCLC 2017: Phase Ib/II savolitinib plus Iressa® in MET-driven NSCLC
OA 09.06 – A Phase Ib Trial of Savolitinib plus Gefitinib for Chinese Patients with EGFR-Mutant MET-Amplified Advanced NSCLC Jin-Ji Yang, Jian Fang, Y. Shu, J. Chang, G. Chen, J. He, W. Li, X. Liu, N. Yang, Caicun Zhou, J. Huang, L. Yang, A.A. Han
Read More
Presentations, Scientific Publications | 17 Oct 2017

WCLC 2017: Phase Ib/II savolitinib plus Tagrisso® in MET-driven NSCLC
OA 09.03 – TATTON Ph Ib Expansion Cohort: Osimertinib plus Savolitinib for Pts with EGFR-Mutant MET-Amplified NSCLC after Progression on Prior EGFR-TKI Myung-Ju Ahn, Ji-Youn Han, Lecia V Sequist, Byoung Chul Cho, J.S. Lee, Sang-We Kim, W. Su, C. T
Read More
Presentations, Scientific Publications | 15 Oct 2017

WCLC 2017: Phase II fruquintinib combination with Iressa in NSCLC
JCSE 01.12 – A Phase II study of fruquintinib in combination with gefitinib in stage IIIb/IV NSCLC patients harboring EGFR activating mutations (NCT02976116) Shun Lu, Jianying Zhou, Xiaomin Niu, Mo Chen, Hongyan Yin, Ye Hua, Weiguo Su Venue: IA
Read More
Presentations, Scientific Publications | 28 Sep 2017

CSCO 2017: Savolitinib Phase Ib in c-MET Gastric Cancer
Phase Ib Trial of the Safety and Antitumor Activity of Savolitinib in Advanced Gastric Cancer Patients with Aberrant c-MET Jifeng Feng, Baorui Liu, Tianshu Liu, Nong Xu, Jianming Xu, Yunpeng Liu, Yuxian Bai, Jin Li, Wei Li, Chunmei Bai, Tao Zhang,
Read More
Download Slides (PDF)
Presentations, Scientific Publications | 28 Sep 2017

CSCO 2017: Theliatinib Phase I Results
Novel EGFR TKI Theliatinib: An Open Label, Dose Escalation Phase I Clinical Trial Lin Shen, Li Zhang, Hongyun Zhao, Wenfeng Fang, Jifang Gong Venue: Chinese Society of Clinical Oncology Annual Meeting Session: Esophageal Cancer Presenter: Jif
Read More
Download Slides (PDF)
Presentations, Scientific Publications | 27 Sep 2017

CSCO 2017: FRESCO In-Depth Analysis
In-depth Analysis of the FRESCO Study: a Randomized, Double-blind, Phase III Trial Evaluating the Efficacy and Safety of Fruquintinib in Patients with 3+ Line Advanced Colorectal Cancer Shukui QIN*, Jin LI*, Yuxian BAI, Yanhong DENG, Lei YANG, Zhen
Read More
Download Slides (PDF)
Presentations, Scientific Publications | 27 Sep 2017

CSCO 2017: Theliatinib Preclinical Study in Esophageal Cancer
Is EGFR a “feasible” target for advanced esophageal cancer treatment? Rongxin Ren, Shiming Fan, Linfang Wang,Min Cheng, Dongxia Shi,  Wei Zhang,Renxiang Tang, Ying Yu, Longxian Jiao, Jun Ni, Haibin Yang, Huaqing Cai,Feng Zhou, Weihan Zhang, Wei
Read More
Corporate presentations, Event, Presentations | 16 Sep 2017

The Royal Society of Medicine 15th Medical Innovations Summit
The Royal Society of Medicine, London, UK Please visit rsm.ac.uk for more information. A video recording of the 20-minute presentation is available. RSM video link Note: there is a 25-second audio error at 2:55.
Read More
View Presentation (PDF)
Corporate presentations, Event, Presentations | 31 Jul 2017

2017 Half-Year Financial Results
Announcement released: 7am BST (2am EDT, 2pm HKT) » See announcement here Presentation webcast & call: 9am BST (4pm HKT) » click here for a video of the webcast US conference call: 9am EDT (2pm BST) » To parti
Read More
View Presentation (PDF)
Presentations, Scientific Publications | 23 Jun 2017

Journal of Clinical Oncology: Biomarker-Based Phase II Trial of Savolitinib in Patients With Advanced PRCC
Toni K. Choueiri, Elizabeth Plimack, Hendrik-Tobias Arkenau, Eric Jonasch, Daniel Y.C. Heng, Thomas Powles, Melanie M. Frigault, Edwin A. Clark, Amir A. Handzel, Humphrey Gardner, Shethah Morgan, Laurence Albiges, and Sumanta Kumar Pal Abstract Pur
Read More
Corporate presentations, Event, Presentations | 21 Jun 2017

Bernstein Conference: China Oncology Day
Mandarin Oriental, Hong Kong
Download Presentation (PDF)
Presentations, Scientific Publications | 5 Jun 2017

ASCO 2017: Fruquintinib Phase III in Metastatic Colorectal Cancer (FRESCO)
A randomized, double-blind, placebo-controlled, multi-centered phase III trial comparing fruquintinib versus placebo plus best supportive care in Chinese patients with metastatic colorectal cancer (FRESCO) Venue: American Society of Clinical Oncol
Read More
View Presentation Slides (PDF)
Presentations, Scientific Publications | 5 Jun 2017

ASCO 2017: Sulfatinib Phase II in Medullary and Differentiated Thyroid Cancer
A phase II multicenter trial of the multitargeted kinase inhibitor sulfatinib in advanced medullary thyroid cancer (MTC) and radioiodine (RAI)-refractory differentiated thyroid cancer (DTC) Venue: American Society of Clinical Oncology Annual Meeti
Read More
Download Poster Presentation (PDF)
1
23